Published in Scand J Urol on January 26, 2015
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol (2005) 2.93
CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax (2011) 2.88
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell (2012) 2.59
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single UK centre: learning curves of two surgeons. BJU Int (2010) 2.12
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol (2007) 1.78
Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res (2004) 1.59
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene (2003) 1.56
Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol (2010) 1.55
Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res (2006) 1.44
LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. Clin Cancer Res (2009) 1.41
Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene (2005) 1.33
Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet (2007) 1.32
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs (2010) 1.30
Chronic pelvic pain due to pelvic congestion syndrome: the role of diagnostic and interventional radiology. Cardiovasc Intervent Radiol (2007) 1.20
Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol (2013) 1.19
The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila) (2014) 1.16
Alterations in beta-catenin expression and localization in prostate cancer. Prostate (2008) 1.16
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer (2013) 1.15
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.08
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol (2006) 1.08
Inherited variants in MYH are unlikely to contribute to the risk of lung carcinoma. Hum Genet (2003) 1.08
Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res (2010) 1.06
Cancer testis antigens: A new paradigm for cancer therapy. Oncoimmunology (2012) 1.06
Caspase 3 in breast cancer. Clin Cancer Res (2003) 1.06
The James Lind Alliance approach to priority setting for prostate cancer research: an integrative methodology based on patient and clinician participation. BJU Int (2011) 1.05
Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature. BJU Int (2014) 1.04
Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol (2010) 1.04
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer (2010) 1.02
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol (2013) 1.02
Recovery of Mycobacterium tuberculosis from sputum treated with cetyl pyridinium chloride. J Clin Microbiol (2009) 1.02
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One (2010) 1.01
Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int (2005) 0.99
The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol (2012) 0.99
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol (2012) 0.99
Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU Int (2008) 0.99
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate (2010) 0.99
Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy. PLoS One (2013) 0.98
Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res (2006) 0.98
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med (2014) 0.98
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res (2013) 0.96
The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. Oncoimmunology (2013) 0.95
Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol (2010) 0.95
Prostate cancer: performance characteristics of combined T₂W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion. Eur Radiol (2014) 0.95
Expression and functional role of negative signalling regulators in tumour development and progression. Int J Cancer (2010) 0.94
Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. Mod Pathol (2007) 0.94
Minimal-preparation CT colon in detection of colonic cancer, the Oxford experience. Age Ageing (2006) 0.93
Case-control study of familial lung cancer risks in UK women. Int J Cancer (2005) 0.93
Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate- or high-risk prostate cancer. AJR Am J Roentgenol (2014) 0.91
The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung Cancer (2006) 0.90
Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future? Exp Dermatol (2008) 0.90
Role and expression of FRS2 and FRS3 in prostate cancer. BMC Cancer (2011) 0.89
Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther (2009) 0.89
Expression and humoral response of A-kinase anchor protein 4 in cervical cancer. Int J Gynecol Cancer (2013) 0.89
Perspectives in drug development for metastatic renal cell cancer. Target Oncol (2010) 0.88
Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev (2009) 0.87
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. Lung Cancer (2008) 0.87
Evaluation of xeroderma pigmentosum XPA, XPC, XPD, XPF, XPB, XPG and DDB2 genes in familial early-onset lung cancer predisposition. Int J Cancer (2006) 0.86
UK guidelines for the systemic treatment of renal cell carcinoma. Br J Hosp Med (Lond) (2009) 0.86
Laser-capture microdissection and transcriptional profiling in archival FFPE tissue in prostate cancer. Methods Mol Biol (2011) 0.86
Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy. J Exp Clin Cancer Res (2013) 0.86
Thalidomide in solid malignancies. J Clin Oncol (2002) 0.85
Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol (2006) 0.85
Diagnosis of gossypiboma of the abdomen and pelvis. AJR Am J Roentgenol (2008) 0.85
Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist (2009) 0.84
The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. J Cancer Res Clin Oncol (2012) 0.84
Prognostic factors in renal cell cancer. BJU Int (2007) 0.84
No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses. PLoS One (2012) 0.83
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ Case Rep (2009) 0.83
Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. Magn Reson Med (2010) 0.80
Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients. Lung Cancer (2007) 0.80
A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int (2010) 0.79
Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 0.79
Thyroid gland rupture after blunt cervical trauma. J Ultrasound Med (2007) 0.79
Plain Radiography May Be Safely Omitted for Selected Major Trauma Patients Undergoing Whole Body CT: Database Study. Emerg Med Int (2012) 0.79
Surgical intervention for mediastinal pancreatic pseudocysts. A case series and review of the literature. JOP (2015) 0.78
Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma. Curr Oncol Rep (2013) 0.78
Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk group. Expert Rev Anticancer Ther (2011) 0.77
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 0.77
Renal cell carcinoma and the use of sorafenib. Ther Clin Risk Manag (2006) 0.77
Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men. BMC Cancer (2014) 0.76
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology (2010) 0.76
Ensuring the right PET scan for the right patient. Lung Cancer (2007) 0.76
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications. Ther Adv Med Oncol (2013) 0.75
Renewed hope for patients with advanced renal cell cancer: Cinderella comes of age. Eur J Cancer (2005) 0.75
Authors' response. Thorax (2013) 0.75
Re: Pheochromocytoma of the urinary bladder. Can J Urol (2008) 0.75
Emergency splenic artery embolization in the treatment of massive bleeding gastric varices. Eur J Gastroenterol Hepatol (2007) 0.75